SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：8
|
作者：
Nash, P. [1 ]
Coates, L. C. [2 ]
Kivitz, A. J. [3 ]
Mease, P. J. [4 ,5 ]
Gladman, D. D. [6 ]
Covarrubias-Cobos, A. [7 ]
Fleishaker, D. [8 ]
Wang, C. [8 ]
Kudlacz, E. [8 ]
Menon, S. [8 ]
Fallon, L. [9 ]
Hendrikx, T. [10 ]
Kanik, K. S. [8 ]
机构：
[1] Univ Queensland, Brisbane, Qld, Australia
[2] Univ Oxford, Oxford, England
[3] Altoona Ctr Clin Res, Duncansville, PA USA
[4] Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Univ Toronto, Toronto Western Hosp, Toronto, ON, Canada
[7] Unidad Reumatol Las Amer SCP, Merida, Mexico
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Canada, Montreal, PQ, Canada
[10] Pfizer Inc, Collegeville, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.3115
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0293
引用
收藏
页码：1010 / 1011
页数：2
相关论文
共 50 条
  • [31] Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
    Nash, Peter
    Coates, Laura C.
    Fleischmann, Roy
    Papp, Kim
    Gomez-Reino, Juan J.
    Kanik, Keith S.
    Wang, Cunshan
    Wu, Joseph
    Hendrikx, Thijs
    Ports, William C.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [32] INTEGRATED EFFICACY ANALYSIS OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Nash, P.
    Coates, L. C.
    Fleischmann, R.
    Papp, K. A.
    Gomez-Reino, J. J.
    Kanik, K. S.
    Wang, C.
    Wu, J.
    Hendrikx, T.
    Ports, W. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 951 - 952
  • [33] Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
    Coates, Laura
    Gladman, Dafna
    Van den Bosch, Filip
    Helliwell, Philip
    Rychlewska-Hanczewska, Anna
    Stanislavchuk, Mykola
    Gilles, Leen
    Gheyle, Lien
    Liu, Ke
    Trivedi, Mona
    Alani, Muhsen
    Besuyen, Robin
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [34] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Wei, Shu Chen
    Damiao, Aderson O.
    Judd, Donna
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
  • [35] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
    Lichtenstein, G. R.
    Loftus, E. V., Jr.
    Wei, S. C.
    Damiao, A. O.
    Judd, D.
    Lawendy, N.
    Chan, G.
    Zhang, H.
    Wang, W.
    Thorpe, A. J.
    Bloom, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
  • [36] Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
    Gladman, Dafna D.
    Nash, Peter
    Mease, Philip J.
    Fitzgerald, Oliver
    Duench, Stephanie
    Cadatal, Mary Jane
    Masri, Karim R.
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [37] Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
    Gladman, Dafna
    Nash, Peter
    Mease, Philip J.
    FitzGerald, Oliver
    Masri, Karim R.
    Duench, Stephanie
    Jane Cadatal, Mary
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2798 - 2801
  • [38] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Ruediger B. Mueller
    Hendrik Schulze-Koops
    Daniel E. Furst
    Stanley B.  Cohen
    Kenneth Kwok
    Lisy Wang
    Tim Killeen
    Johannes von Kempis
    Clinical Rheumatology, 2022, 41 : 1045 - 1055
  • [39] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Mueller, Ruediger B.
    Schulze-Koops, Hendrik
    Furst, Daniel E.
    Cohen, Stanley B.
    Kwok, Kenneth
    Wang, Lisy
    Killeen, Tim
    von Kempis, Johannes
    CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055
  • [40] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine I.
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rizo Rodriguez, Juan Cruz
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
12345